Biotechnology Rare Disease Pharmaceuticals

neu

NEU: Rare Disease Royalty King - Exceptional Quality, Expensive Entry

Updated 8 Oct 2025

Monopoly Rett syndrome treatment with 83.4% margins and A$222m cash. Fair value A$10.46 vs current A$16.93 suggests 62% overvaluation despite exceptional business quality.

View note